TITLE

Complications of collagenous colitis

AUTHOR(S)
Freeman, Hugh James; Hackam, David J.
PUB. DATE
March 2008
SOURCE
World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1643
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Microscopic forms of colitis have been described, including collagenous colitis. This disorder generally has an apparently benign clinical course. However, a number of gastric and intestinal complications, possibly coincidental, may develop with collagenous colitis. Distinctive inflammatory disorders of the gastric mucosa have been described, including lymphocytic gastritis and collagenous gastritis. Celiac disease and collagenous sprue (or collagenous enteritis) may occur. Colonic ulceration has been associated with use of nonsteroidal anti-inflammatory drugs, while other forms of inflammatory bowel disease, including ulcerative colitis and Crohn's disease, may evolve from collagenous colitis. Submucosal "dissection", colonic fractures or mucosal tears and perforation from air insufflation during colonoscopy may occur and has been hypothesized to be due to compromise of the colonic wall from submucosal collagen deposition. Similar changes may result from increased intraluminal pressure during barium enema contrast studies. Finally, malignant disorders have also been reported, including carcinoma and lymphoproliferative disease.
ACCESSION #
31436352

 

Related Articles

  • Research brief: NSAIDs trigger bowel disease relapses.  // GP: General Practitioner;3/3/2006, p9 

    The article reports that non-selective nonsteroidal anti-inflammatory agents may cause relapses in patients with ulcerative colitis or Crohn's disease, according to a study from Great Britain.

  • Orofacial manifestations of gastrointestinal disorders. Jurge, Sabine; Hegarty, Anne M.; Hodgson, Tim // British Journal of Hospital Medicine (17508460);Sep2014, Vol. 75 Issue 9, p497 

    No abstract available.

  • Tolerance of Nonsteroidal Antiinflammatory Drugs in Patients With Inflammatory Bowel Disease. Bonner, Gregory F.; Walczak, Michelle; Kitchen, Laurel; Bayona, Manuel // American Journal of Gastroenterology;Aug2000, Vol. 95 Issue 8, p1946 

    OBJECTIVE: We sought to examine whether use of nonsteroidal antiinflammatory drugs (NSAIDs) in an outpatient inflammatory bowel disease (IBD) population is associated with an increased likelihood of active disease. METHODS: We reviewed records of initial outpatient visits of IBD patients to the...

  • Effects of Nonsteroidal Antiinflammatory Drugs on Inflammatory Bowel Disease: A Case-Control Study. Felder, Joseph B.; Korelitz, Burton I.; Rajapakse, Ramona; Schwarz, Samuel; Horatagis, Angelo P.; Gleim, Gilbert // American Journal of Gastroenterology;Aug2000, Vol. 95 Issue 8, p1949 

    OBJECTIVE: The aim of this study was to determine whether a relationship exists between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and exacerbation or onset of inflammatory bowel disease (IBD). METHODS: Sixty consecutive IBD patients admitted to the hospital were carefully...

  • Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane reviews. Balzola, Federico; Cullen, Garret; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2013, Vol. 14 Issue 1, p24 

    The article presents a study that reviews the difference between various formulations of 5-aminosalicylic acid in patients with ulcerative colitis. It describes the method of the study that observes 2925 ulcerative colitis patients using randomized controlled trials. It outlines the findings of...

  • Cytokines in inflammatory bowel disease. Neurath, Markus F. // Nature Reviews Immunology;May2014, Vol. 14 Issue 5, p329 

    Cytokines have a crucial role in the pathogenesis of inflammatory bowel diseases (IBDs), such as Crohn's disease and ulcerative colitis, where they control multiple aspects of the inflammatory response. In particular, the imbalance between pro-inflammatory and anti-inflammatory cytokines that...

  • Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis. Atzeni, Fabiola; Ardizzone, Sandro; Bertani, Luca; Antivalle, Marco; Batticciotto, Alberto; Sarzi-Puttini, Piercarlo; Eliakim, Abraham R. // World Journal of Gastroenterology;5/28/2009, Vol. 15 Issue 20, p2469 

    Inflammatory bowel diseases (IBDs), particularly Crohn's disease (CD) and ulcerative colitis (UC), are associated with a variety of extra-intestinal manifestations (EIMs). About 36% of IBD patients have at least one EIM, which most frequently affect the joints, skin, eyes and the biliary tract....

  • Soluble Syndecan-1 Levels Are Elevated in Patients with Inflammatory Bowel Disease. Yablecovitch, Doron; Stein, Assaf; Shabat-Simon, Maytal; Naftali, Timna; Gabay, Gila; Laish, Ido; Oren, Asaf; Konikoff, Fred // Digestive Diseases & Sciences;Aug2015, Vol. 60 Issue 8, p2419 

    Background: Syndecan-1 plays a central role in maintaining normal intestinal barrier function. Shedding of syndecan-1, reflected by soluble syndecan-1 serum concentrations, is highly regulated by inflammation. Aim: To determine soluble syndecan-1 levels in inflammatory bowel disease patients and...

  • Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study. Hensley, Abigail; Beales, Ian L. P. // Pharmaceuticals;Sep2015, Vol. 8 Issue 3, p512 

    Patients with inflammatory bowel disease (IBD) often have associated conditions, for which anti-inflammatory medication with cyclo-oxygenase (COX) inhibitors may be helpful. The current evidence is conflicting regarding the role of COX-inhibitors in causing relapse in IBD. This case-control...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics